← The Wire
AVTXNasdaq
Avalo Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1534120
Developing IL-1β-based treatments for immune-mediated inflammatory diseases, including their lead candidate abdakibart for hidradenitis suppurativa
red 8-K · 90d
$776M
Market cap
$19.29
Last close
+6.0%
1D
+12.9%
5D
1.6M
Volume
Price · last 39 sessions+40.0%
May 4L $12.74 · H $22.87Jun 29
300
Total filings
Jun 23, 2026
Last filing
12/31
Fiscal year end
8-K/ACompany UpdateJun 24, 20248-K/ACompany UpdateJun 3, 20248-K/AMaterial Agreement · Equity IssuanceDec 11, 20198-K/ADelisting NoticeSep 19, 20198-K/ACompany UpdateDec 4, 20188-K/ACompany UpdateMay 4, 20188-K/ACompany UpdateJan 24, 20188-K/AExecutive ChangeNov 29, 20178-K/ADelisting NoticeOct 18, 20178-K/ADelisting NoticeAug 25, 20178-K/AShareholder VoteJul 7, 2017
Insider Activity
In the 90 days to Mar 16, 2026: 1 sold $412K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Doyle MittieChief Medical Officer | Sell | 25,492 | $16.15 | $412K |
| Nov 14, 2025 | Goldman JonathanDirector | Sell | 8,200 | $14.35 | $118K |
| Nov 14, 2025 | Goldman JonathanDirector | Sell | 3,167 | $14.30 | $45K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance